Denali Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Denali Therapeutics Stock Summary

Denali Therapeutics competes with Stoke Therapeutics, Black Diamond, 4D Molecular, Ascendis Pharma, and Apellis Pharmaceuticals. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.

Denali Therapeutics Key Financial Ratios

Denali Therapeutics Key Balance Sheet Accounts

Denali Therapeutics Key Income Statement Accounts

Denali Therapeutics Key Cash Accounts

Denali Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Denali Therapeutics's current stock value. Our valuation model uses many indicators to compare Denali Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Denali Therapeutics competition to find correlations between indicators driving Denali Therapeutics's intrinsic value. More Info.Denali Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Denali Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Denali Therapeutics' earnings, one of the primary drivers of an investment's value.

Denali Therapeutics Systematic Risk

Today, most investors in Denali Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Denali Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Denali Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Denali Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Denali Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Denali Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Denali Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Denali Therapeutics's daily price indicators and compare them against related drivers.

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.